C4 Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CCCC$3.00-4.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensive Income (Loss) · Accumulated Deficit · TotalStockholders' Equity
Shares · Amount
Balance as of December 31, 2025	96,914,418	$9	$995,221	$50	$(738,693)	$256,587
Issuance of common stock upon exercise of warrants	6,187,000	1	—	—	—	1
Issuance of common stock upon exercise of stock options	271,175	—	605	—	—	605
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	606,925	—	(200)	—	—	(200)
Issuance of common stock under employee stock purchase plan	43,361	—	56	—	—	56
Stock-based compensation	—	—	2,671	—	—	2,671
Change in unrealized loss, net on marketable securities	—	—	—	(372)	—	(372)
Net loss	—	—	—	—	(25,129)	(25,129)
Other	13,471	—	28	—	—	28
Balance as of March 31, 2026	104,036,350	$10	$998,381	$(322)	$(763,822)	$234,247
Issuance of common stock upon exercise of warrants	9,508,500	1	—	—	—	1
Issuance of common stock pursuant to the at-the-market equity program, net	9,273,620	1	33,547	—	—	33,548
Issuance of common stock upon exercise of stock options	77,657	—	176	—	—	176
Stock-based compensation	—	—	3,036	—	—	3,036
Change in unrealized loss, net on marketable securities	—	—	—	(122)	—	(122)
Net loss	—	—	—	—	(23,635)	(23,635)
Other	9,629	—	14	—	—	14
Balance as of June 30, 2026	122,905,756	$12	$1,035,154	$(444)	$(787,457)	$247,265
Issuance of common stock upon cashless exercise of warrants, net of shares withheld	8,194,779	1	(1)	—	—	—
Issuance of common stock upon exercise of stock options	85,818	—	225	—	—	225
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	11,403	—	(39)	—	—	(39)
Issuance of common stock under employee stock purchase plan	105,461	—	173	—	—	173
Stock-based compensation	—	—	2,980	—	—	2,980
Change in unrealized loss, net on marketable securities	—	—	—	(619)	—	(619)
Net loss	—	—	—	—	(21,843)	(21,843)
Other	5,991	—	26	—	—	26
Balance as of September 30, 2026	131,309,208	$13	$1,038,518	$(1,063)	$(809,300)	$228,168

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount
Balance as of December 31, 2024	70,625,899	$7	$849,625	$53	$(633,699)	$215,986
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	321,342	—	(155)	—	—	(155)
Issuance of common stock under employee stock purchase plan	35,589	—	109	—	—	109
Stock-based compensation	—	—	5,507	—	—	5,507
Change in unrealized loss, net on marketable securities	—	—	—	(10)	—	(10)
Net loss	—	—	—	—	(26,322)	(26,322)
Other	6,831	—	25	—	—	25
Balance as of March 31, 2025	70,989,661	$7	$855,111	$43	$(660,021)	$195,140
Stock-based compensation	—	—	4,992	—	—	4,992
Change in unrealized loss, net on marketable securities	—	—	—	(73)	—	(73)
Net loss	—	—	—	—	(26,020)	(26,020)
Other	17,422	—	25	—	—	25
Balance as of June 30, 2025	71,007,083	$7	$860,128	$(30)	$(686,041)	$174,064
Issuance of common stock pursuant to the at-the-market equity program, net	2,950,225	—	7,526	—	—	7,526
Issuance of common stock upon exercise of stock options	50,000	—	107	—	—	107
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	14,868	—	(24)	—	—	(24)
Issuance of common stock under employee stock purchase plan	135,114	—	164	—	—	164
Stock-based compensation	—	—	4,593	—	—	4,593
Change in unrealized gain, net on marketable securities	—	—	—	117	—	117
Net loss	—	—	—	—	(32,166)	(32,166)
Other	17,225	—	27	—	—	27
Balance as of September 30, 2025	74,174,515	$7	$872,521	$87	$(718,207)	$154,408

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.